New CRISPR variant Cas12a2 selectively kills cancer cells without harming healthy ones

A paper published in Nature on 6 May 2026 describes a new class of CRISPR tool, Cas12a2, that destroys cells displaying a target RNA signature rather than editing DNA. The mechanism — “RNA-triggered cell killing” — opens a precision-medicine route to cancers and viral infections that has been hard to reach with conventional gene-editing.

In dish experiments, Cas12a2 cut the growth of human lung cancer cells carrying a KRAS mutation by 50%, comparable to established chemotherapy drugs like cisplatin. Crucially, cells with healthy KRAS were unaffected. The system uses the cancer-specific RNA itself as a trigger, then shreds the surrounding DNA — a self-targeting kill switch.

The work is still pre-clinical and faces the usual translation gauntlet (delivery, off-target effects, immunogenicity), but it widens the conceptual toolbox for CRISPR therapeutics beyond rare monogenic disease into selectively destroying mutated or virally infected cells.

Sources: University of Utah · Nature commentary